LP
CARM

LMR Partners’s Carisma Therapeutics CARM Stock Holding History

LMR Partners’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,787
Closed -$41K – 1126
2022
Q3 		$41K Hold
4,787
– – ﹤0.01% 1112
2022
Q2 		$78K Buy
+4,787
New +$54.8K ﹤0.01% 1117
2021
Q2 		– Sell
-5,050
Closed -$263K – 1139
2021
Q1 		$263K Buy
5,050
+4,490
+802% +$212K 0.01% 754
2020
Q4 		$15K Buy
+560
New +$14.2K ﹤0.01% 478

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BWA
Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's CARM Position: Q4 2022 in Review

LMR Partners sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 4,787 shares — an estimated $41K sold.

LMR Partners first reported a position in CARM in Q4 2020 and held it in 4 quarters. The position peaked at $263K in Q1 2021. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

  • LMR Partners reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 4,787 Carisma Therapeutics shares in Q4 2022, an estimated $41K.
  • LMR Partners first reported a position in Carisma Therapeutics in Q4 2020 and held it in 4 quarters.
  • LMR Partners's Carisma Therapeutics position peaked at $263K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.